- Home
- SAR vs INBX Comparison
SAR vs INBX Comparison
Compare SAR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAR
- INBX
- Stock Information
- Founded
- SAR 2007
- INBX 2010
- Country
- SAR United States
- INBX United States
- Employees
- SAR N/A
- INBX N/A
- Industry
- SAR Investment Managers
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SAR Finance
- INBX Health Care
- Exchange
- SAR Nasdaq
- INBX Nasdaq
- Market Cap
- SAR 402.9M
- INBX 345.8M
- IPO Year
- SAR 2007
- INBX 2020
- Fundamental
- Price
- SAR $24.52
- INBX $26.54
- Analyst Decision
- SAR Hold
- INBX Hold
- Analyst Count
- SAR 5
- INBX 2
- Target Price
- SAR $24.56
- INBX N/A
- AVG Volume (30 Days)
- SAR 111.1K
- INBX 112.9K
- Earning Date
- SAR 10-07-2025
- INBX 11-13-2025
- Dividend Yield
- SAR 12.22%
- INBX N/A
- EPS Growth
- SAR 105.87
- INBX N/A
- EPS
- SAR 2.47
- INBX N/A
- Revenue
- SAR $142,495,705.00
- INBX $1,400,000.00
- Revenue This Year
- SAR N/A
- INBX N/A
- Revenue Next Year
- SAR $1.97
- INBX N/A
- P/E Ratio
- SAR $9.93
- INBX N/A
- Revenue Growth
- SAR N/A
- INBX N/A
- 52 Week Low
- SAR $21.10
- INBX $10.81
- 52 Week High
- SAR $26.49
- INBX $30.23
- Technical
- Relative Strength Index (RSI)
- SAR 41.84
- INBX 52.65
- Support Level
- SAR $24.08
- INBX $27.51
- Resistance Level
- SAR $24.71
- INBX $28.86
- Average True Range (ATR)
- SAR 0.30
- INBX 1.38
- MACD
- SAR -0.09
- INBX -0.37
- Stochastic Oscillator
- SAR 28.21
- INBX 8.54
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.